Eyal Mishani

Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes

Menachem Motiei, Oshra Betzer, Rachela Popovtzer, 2017, BiOS.

Amyloid-β positron emission tomography imaging probes: a critical review.

Habib Zaidi, Sung-Cheng Huang, Abass Alavi, 2013, Journal of Alzheimer's disease : JAD.

Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.

Eyal Mishani, Ur Metser, U. Metser, 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

18F-Fluoride positron emission tomography and positron emission tomography/computed tomography.

Eyal Mishani, Ur Metser, U. Metser, 2007, Seminars in nuclear medicine.

High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.

Galith Abourbeh, Eyal Mishani, Alexander Levitzki, 2005, Journal of medicinal chemistry.

Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.

Galith Abourbeh, Eyal Mishani, Alexander Levitzki, 2004, Nuclear medicine and biology.

Differentiating Between Cancer and Inflammation: A Metabolic-Based Method for Functional Computed Tomography Imaging.

Menachem Motiei, Hana Panet, Oshra Betzer, 2016, ACS nano.